SCHEMBL2932828

SCHEMBL2932828

NC(=O)c1cccc(-c2cccs2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.61
ALDH1A1 P00352 6/20 0.61
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
MAPT P10636 4/20 0.61
HPGD P15428 4/20 0.61
TDP1 Q9NUW8 2/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
RAB9A P51151 6/20 0.51
NPC1 O15118 5/20 0.51
POLB P06746 1/20 0.51
AURKA O14965 1/20 0.47
JAK2 O60674 1/20 0.47
NTRK1 P04629 1/20 0.47
RET P07949 1/20 0.47
PIM1 P11309 1/20 0.47
FGFR1 P11362 1/20 0.47
PRKACA P17612 1/20 0.47
LTK P29376 1/20 0.47
KDR P35968 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2972148 0.85 KDM4E (0.63) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL9081166 0.83 KDM4E (0.61) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL9792961 0.80 PIM1 (0.50) KDM4ETDP1PIM1TSHR
SCHEMBL12467591 0.80 KDM4E (0.56) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL5014392 0.79 ALDH1A1 (0.59) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL498897 0.78 KDM4E (1.00) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL5014381 0.76 SMN1; SMN2 (0.64) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL6646535 0.74 AURKA (0.48) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL12753356 0.74 HSD11B1 (0.61) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL3100883 0.74 PIM1 (0.48) KDM4EALDH1A1TDP1PIM1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US claimed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US claimed
EP-1846424-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2007-10-24 EP claimed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US claimed
WO-2006086600-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-08-17 WO claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP disclosed
US-20090075936-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-03-19 US disclosed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US disclosed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189806-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 KDM4E 1640/4885ALDH1A1 3902/4885MEN1 2309/4885
US-20090075936-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 KDM4E 1640/4885ALDH1A1 3902/4885MEN1 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.